Tobias Stöger

Dr. Tobias Stöger

Institute of Lung Biology and Disease (ILBD)/Comprehensive Pneumology Center (CPC); Helmholtz Zentrum München, Germany
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMaximilian Strunz
Maximilian Strunz
LSLukas M. Simon
Lukas M. Simon
MAMeshal Ansari
Meshal Ansari
JKJaymin J. Kathiriya
Jaymin J. Kathiriya
IAIlias Angelidis
Ilias Angelidis
HSHerbert B. Schiller
Herbert B. Schiller
The cell type specific sequences of transcriptional programs during lung regeneration have remained elusive. Using time-series single cell RNA-seq of the bleomycin lung injury model, we resolved transcriptional dynamics for 28 cell types. Trajectory modeling together with lineage tracing revealed that airway and alveolar stem cells converge on a unique Krt8 + transitional stem cell state during alveolar regeneration. These cells have squamous morphology, feature p53 and NFkB activation and display transcriptional features of cellular senescence. The Krt8+ state appears in several independent models of lung injury and persists in human lung fibrosis, creating a distinct cell–cell communication network with mesenchyme and macrophages during repair. We generated a model of gene regulatory programs leading to Krt8+ transitional cells and their terminal differentiation to alveolar type-1 cells. We propose that in lung fibrosis, perturbed molecular checkpoints on the way to terminal differentiation can cause aberrant persistence of regenerative intermediate stem cell states.

3 March 2010 in Particle and Fibre Toxicology
Verified
Journal Article
Open access
PDF file
Sonu BhaskarSonu Bhaskar
Sonu Bhaskar
Furong TianFurong Tian
Furong Tian
TSTobias Stöger
Tobias Stöger
WKWolfgang Kreyling
Wolfgang Kreyling
Jesus M De La FuenteJesus M De La Fuente
Jesus M De La Fuente
DRDaniel Razansky
Daniel Razansky
Nanotechnology has brought a variety of new possibilities into biological discovery and clinical practice. In particular, nano-scaled carriers have revolutionalized drug delivery, allowing for therapeutic agents to be selectively targeted on an organ, tissue and cell specific level, also minimizing exposure of healthy tissue to drugs. In this review we discuss and analyze three issues, which are considered to be at the core of nano-scaled drug delivery systems, namely functionalization of nanocarriers, delivery to target organs andin vivoimaging. The latest developments on highly specific conjugation strategies that are used to attach biomolecules to the surface of nanoparticles (NP) are first reviewed. Besides drug carrying capabilities, the functionalization of nanocarriers also facilitate their transport to primary target organs. We highlight the leading advantage of nanocarriers, i.e. their ability to cross the blood-brain barrier (BBB), a tightly packed layer of endothelial cells surrounding the brain that prevents high-molecular weight molecules from entering the brain. The BBB has several transport molecules such as growth factors, insulin and transferrin that can potentially increase the efficiency and kinetics of brain-targeting nanocarriers. Potential treatments for common neurological disorders, such as stroke, tumours and Alzheimer's, are therefore a much sought-after application of nanomedicine. Likewise any other drug delivery system, a number of parameters need to be registered once functionalized NPs are administered, for instance their efficiency in organ-selective targeting, bioaccumulation and excretion. Finally, directin vivoimaging of nanomaterials is an exciting recent field that can provide real-time tracking of those nanocarriers. We review a range of systems suitable forin vivoimaging and monitoring of drug delivery, with an emphasis on most recently introduced molecular imaging modalities based on optical and hybrid contrast, such as fluorescent protein tomography and multispectral optoacoustic tomography. Overall, great potential is foreseen for nanocarriers in medical diagnostics, therapeutics and molecular targeting. A proposed roadmap for ongoing and future research directions is therefore discussed in detail with emphasis on the development of novel approaches for functionalization, targeting and imaging of nano-based drug delivery systems, a cutting-edge technology poised to change the ways medicine is administered.

4 November 2020 in Nature
Verified
Journal Article
Closed access
PDF file
TCThomas M. Conlon
Thomas M. Conlon
GJGerrit John-Schuster
Gerrit John-Schuster
DHDanijela Heide
Danijela Heide
DPDominik Pfister
Dominik Pfister
MLMareike Lehmann
Mareike Lehmann
AYAli Önder Yildirim
Ali Önder Yildirim

2 January 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ALAnke-Gabriele Lenz
Anke-Gabriele Lenz
EKErwin Karg
Erwin Karg
EBEllen Brendel
Ellen Brendel
HHHelga Hinze-Heyn
Helga Hinze-Heyn
KMKonrad L. Maier
Konrad L. Maier
OSOtmar Schmid
Otmar Schmid
The biological effects of inhalable nanoparticles have been widely studied in vitro with pulmonary cells cultured under submerged and air-liquid interface (ALI) conditions. Submerged exposures are experimentally simpler, but ALI exposures are physiologically more realistic and hence potentially biologically more meaningful. In this study, we investigated the cellular response of human alveolar epithelial-like cells (A549) to airborne agglomerates of zinc oxide (ZnO) nanoparticles at the ALI, compared it to the response under submerged culture conditions, and provided a quantitative comparison with the literature data on different types of particles and cells. For ZnO nanoparticle doses of 0.7 and 2.5μg ZnO/cm2 (or 0.09 and 0.33cm2ZnO/cm2), cell viability was not mitigated and no significant effects on the transcript levels of oxidative stress markers (HMOX1, SOD-2 and GCS) were observed. However, the transcript levels of proinflammatory markers (IL-8, IL-6, and GM-CSF) were induced to higher levels under ALI conditions. This is consistent with the literature data and it suggests that in vitro toxicity screening of nanoparticles with ALI cell culture systems may produce less false negative results than screening with submerged cell cultures. However, the database is currently too scarce to draw a definite conclusion on this issue.

15 February 2024 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
SSShanshan Song
Shanshan Song
FDFransien van Dijk
Fransien van Dijk
GVGwenda F. Vasse
Gwenda F. Vasse
QLQiongliang Liu
Qiongliang Liu
IGIrene F. Gosselink
Irene F. Gosselink
BMBarbro N. Melgert
Barbro N. Melgert
Rationale: Microplastics are a pressing global concern, and inhalation of microplastic fibers has been associated with interstitial and bronchial inflammation in flock workers. However, how microplastic fibers affect the lungs is unknown. Objectives: Our aim was to assess the effects of 12 × 31 μm nylon 6,6 (nylon) and 15 × 52 μm polyethylene terephthalate (polyester) textile microplastic fibers on lung epithelial growth and differentiation. Methods: We used human and murine alveolar and airway-type organoids as well as air–liquid interface cultures derived from primary lung epithelial progenitor cells and incubated these with either nylon or polyester fibers or nylon leachate. In addition, mice received one dose of nylon fibers or nylon leachate, and, 7 days later, organoid-forming capacity of isolated epithelial cells was investigated. Measurements and Main Results: We observed that nylon microfibers, more than polyester, inhibited developing airway organoids and not established ones. This effect was mediated by components leaching from nylon. Epithelial cells isolated from mice exposed to nylon fibers or leachate also formed fewer airway organoids, suggesting long-lasting effects of nylon components on epithelial cells. Part of these effects was recapitulated in human air–liquid interface cultures. Transcriptomic analysis revealed upregulation of Hoxa5 after exposure to nylon fibers. Inhibiting Hoxa5 during nylon exposure restored airway organoid formation, confirming Hoxa5’s pivotal role in the effects of nylon. Conclusions: These results suggest that components leaching from nylon 6,6 may especially harm developing airways and/or airways undergoing repair, and we strongly encourage characterization in more detail of both the hazard of and the exposure to microplastic fibers.

18 March 2016 in Cell Death & Differentiation
Verified
Journal Article
Closed access
SCS Chen
S Chen
IKI E Kammerl
I E Kammerl
OVO Vosyka
O Vosyka
TBT Baumann
T Baumann
YYY Yu
Y Yu
TSTobias Stöger
Tobias Stöger